Story
Novo Nordisk Stock Slides After Deutsche Bank Downgrade to 'Sell'

Shares of Novo Nordisk (NOVOb) declined on Tuesday after Deutsche Bank downgraded the pharmaceutical company's stock, amplifying investor concerns about its growth trajectory and competitive standing.
Deutsche Bank Cites Uncertainty
Deutsche Bank analyst Emmanuel Papadakis cut the rating on Novo Nordisk to 'Sell' from a previous 'Hold', making it one of the most bearish calls on the stock from a major investment bank. The firm also reduced its price target on the shares to 265 Danish kroner from 290 kroner.
The downgrade was prompted by what the bank described as mixed results from earlier in the month and "material uncertainty" ahead of Novo Nordisk's upcoming capital markets day. In response, the stock fell 2.4% to trade at 297.8 Danish kroner.
A Pattern of Investor Concern
The downgrade adds to a challenging backdrop for Novo Nordisk that has been building since its Q2 2026 earnings release on August 4. Despite management raising its full-year outlook, the stock sold off as investors focused on several underlying issues:
Ad- The prescription trajectory for its key Wegovy pill came in slightly below analyst models.
- The company reported pipeline disappointments, including the failed trial for its Ziltivekimab cardiovascular drug.
This sentiment was reinforced by a recent downgrade to 'Hold' from Berenberg on August 12. The cumulative weight of cautious analyst commentary has kept the stock significantly below its 52-week high of 410 kroner.
Competitive and Market Context
Pressure is also mounting from rival Eli Lilly, which is seen as widening its lead in the GLP-1 obesity drug market. Eli Lilly's oral weight-loss treatment received its first European regulatory approval in August, posing a direct challenge to Novo Nordisk's franchise.
Tuesday's decline in Novo Nordisk shares was company-specific, occurring while broader U.S. equity markets like the S&P 500 and Nasdaq posted modest gains. The Deutsche Bank note appeared to crystallize existing investor anxieties, sending the shares lower even as the company's share buyback program offered limited support.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.